prikaz prve stranice dokumenta Paklitaksel - od biljke do lijeka
  Download
PDF 5.88 MB
professional thesis
Paklitaksel - od biljke do lijeka
Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry, 2016. urn:nbn:hr:163:533533
Pejković, Petra
University of Zagreb
Faculty of Pharmacy and Biochemistry

Institutional repository: Repository of Faculty of Pharmacy and Biochemistry University of Zagreb

Cite this document

Pejković, P. (2016). Paklitaksel - od biljke do lijeka (Professional thesis). Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:533533

Pejković, Petra. "Paklitaksel - od biljke do lijeka." Professional thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2016. https://urn.nsk.hr/urn:nbn:hr:163:533533

Pejković, Petra. "Paklitaksel - od biljke do lijeka." Professional thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2016. https://urn.nsk.hr/urn:nbn:hr:163:533533

Pejković, P. (2016). 'Paklitaksel - od biljke do lijeka', Professional thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, accessed 26 November 2024, https://urn.nsk.hr/urn:nbn:hr:163:533533

Pejković P. Paklitaksel - od biljke do lijeka [Professional thesis]. Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry; 2016 [cited 2024 November 26] Available at: https://urn.nsk.hr/urn:nbn:hr:163:533533

P. Pejković, "Paklitaksel - od biljke do lijeka", Professional thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, 2016. Available at: https://urn.nsk.hr/urn:nbn:hr:163:533533

Metadata
TitlePaklitaksel - od biljke do lijeka
AuthorPetra Pejković
MentorSanda Vladimir-Knežević (mentor)
Committee memberJelena Filipović-Grčić (predsjednik povjerenstva)
Committee memberSanda Vladimir-Knežević (član povjerenstva)
Committee memberDubravko Jelić (član povjerenstva)
MBZ: 301280
GranterUniversity of Zagreb
Faculty of Pharmacy and Biochemistry
Zagreb
Defense date and country2016, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Pharmacy
Pharmacy
Abstract
Bioaktivne tvari biljnog podrijetla dragocjen su ishodni materijal za razvoj novih lijekova. Brojna znanstvena istraživanja usmjerena su otkrivanju novih lijekova antitumorskog djelovanja budući da je karcinom rastući svjetski zdravstveni problem i drugi glavni uzrok smrtnosti nakon kardiovaskularnih bolesti. Paklitaksel je otkriven upravo u sklopu jednog takvog znanstvenog projekta u kori pacifičke tise (Taxus brevifolia Nutt.).Danas je paklitaksel dio standardne terapije u liječenju različitih vrsta karcinoma, bilo u početnom ili u znapredovalom stadiju. Odobrene terapijske indikacije obuhvaćaju karcinom dojke, jajnika i pluća te Kaposijev sarkom povezan s AIDS-om. Cilj ovog specijalističkog rada bio je prikupiti i obraditi relevantna znanstvena istraživanja te pružiti pregled odnosa molekulske strukture i djelovanja paklitaksela, biosintetskog i sintetskog puta dobivanja, mehanizma djelovanja te farmakokinetičkog i kliničkog profila. Posebna pozornost posvećena je razumijevanju mehanizama rezistencije na paklitaksel i neželjenih učinaka, što je veliki poticaj razvoju suvremenih formulacija lijeka povećane selektivnosti i djelotvornosti te smanjenih toksičnih učinaka. U razvoju novih formulacija paklitaksela najčešće se koriste nanočestice, liposomi, ciklodekstrini, analozi teprolijekovi. Dosadašnje znanstvene spoznaje ukazuju na velik potencijal primjene novih formulacija paklitaksela te potiču buduća istraživanja.
Abstract (english)
Bioactive substances derived from plants are a valuable source of medicines. Numerous scientific research projects are focused on discovery of new anticancer agents since cancer is a growing world health problem and the second major cause of death after cardiovascular diseases. In one such scientific project paclitaxel was discovered as the major substance in the bark of pacific yew (Taxus brevifolia Nutt.). Today paclitaxel is a standard therapy in the treatment of different types of carcinoma, both in early and advanced stages. It is approved for treatment of breast cancer, ovarian cancer, lung cancer and AIDS-related Kaposi's sarcoma. The aim of this work was to collect and analyse the relevant scientific research and give overview of molecular structure and activity relationship of paclitaxel, biosynthetic and synthetic pathways, mechanism of action, pharmacokinetic and clinical profiles. Special focus was put on understanding of resistance mechanisms to paclitaxel as well as adverse events which are the important impulses for development of new formulations with enhanced selectivity and efficiency, and reduced toxic effects. The most used approaches for developing new formulations of paclitaxel are nanoparticles, liposomes, cyclodectrins, analogues and prodrugs. Current scientific data indicate a great potential for the use of new paclitaxel formulations and encourage further research.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:163:533533
Study programmeTitle: Drug development
Study programme type: university
Study level: postgraduate specialist
Academic / professional title: sveučilišni magistar/sveučilišna magistra razvoja lijekova (sveučilišni magistar/sveučilišna magistra razvoja lijekova)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2017-01-13 10:01:36